The Personalised Medicine Consortium (PMC) of Luxembourg is an initiative with the aim to support research and to make Luxembourg a leader in the adoption of personalised medicine into the national healthcare system. It brings together the Luxembourg Institute of Health (LIH), the LCSB (Luxembourg Centre for Systems Biomedicine), IBBL (Integrated BioBank of Luxembourg), the Laboratoire National de Santé (LNS), the Life Sciences Research Unit (LSRU) of the University of Luxembourg (UNI).

The PMC is led by an Executive Board consisting of Catherine Larue (CEO of IBBL), Rudi Balling (CEO of LCSB), Ulf Nehrbass (CEO of LIH), Friedrich Mühlschlegel (CEO of LNS) and Iris Behrmann (Prof LSRU/UNI). The PMC’s initial areas of focus were cancer, diabetes and Parkinson’s disease and multiple collaborative projects were successfully launched and executed. Recently the scope of the PMC has been extended to include other diseases and areas of interest (e.g. big data).

The PMC Fund

The PMC is keen to build new collaborations between clinicians and researchers from Luxembourg and to foster new synergies. To aid in this process, the PMC has developed a fund to ‘pump prime’ new initiatives. This program was successfully launched in 2014/2015 and we are pleased to announce the new call for 2018 launched on 1st September 2017.

The expectation is that the funding will be used to initiate new collaborative research projects on biomedical research between clinicians and researchers and who are based in different research institutions. Priority will be given to projects that are novel and innovative, that are establishing new collaborations within Luxembourg and where preliminary data is needed prior to submitting an application to an external funding agency.

The main expected return on investment of such funding relies on:

  • Ÿ Solving unmet clinical needs with innovative approach
  • Ÿ Fostering research interactions between the three biomedical research institutes of Luxembourg
  • Ÿ Enabling researchers/clinicians to develop this project into an externally funding project if successful

Practical Information

A minimum of two of the PMC funding organisations (IBBL-LIH-LCSB-LNS-LSRU/UNI) must be involved in each funding application (ideally more). For full details about the call, the conditions of eligibility and the application process, you can download the PMC FUND Overview & Guidelines.

Call deadlines

ŸThe 2018 call for proposals was launched on 1st September 2017. Application forms should then be completed and submitted to by 15th October 2017.

Call documents

Ÿ PMC FUND Overview & Guidelines:
Download PDF

Ÿ PMC FUND Application Form:
Download PDF


If you have any question, please contact Angela HOGAN:

Tel:  +352 26 970 – 542


You may be interested in:

  • The Personalised Medicine Consortium reveals the winners of its [...]

    On December 9th, the Personalised Medicine Consortium (PMC) announced this year’s winners of its Pump Prime Fund […]

  • Progress for early detection of colon cancer

    Three years of successful collaboration between Luxembourg’s researchers, clinicians and IBBL (Integrated BioBank of Luxembourg) have led […]

  • Shaping Europe’s Vision for Personalised Medicine

    Considered a European expert on biomarkers, IBBL’s CEO, Dr Catherine Larue, was asked to contribute to the […]